You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Dow
Harvard Business School
Johnson and Johnson

Last Updated: June 4, 2020

DrugPatentWatch Database Preview

Selegiline hydrochloride - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for selegiline hydrochloride and what is the scope of patent protection?

Selegiline hydrochloride is the generic ingredient in three branded drugs marketed by Somerset, Apotex, Dava Pharms Inc, Lannett Co Inc, Rising, Bausch, Acp Nimble, Apotex Inc, Boscogen, Chartwell Molecules, G And W Labs Inc, MLV, and Mylan, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for selegiline hydrochloride. Four suppliers are listed for this compound.

Recent Clinical Trials for selegiline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OxfordN/A
University of South FloridaPhase 4
Mood and Anxiety Research, IncPhase 3

See all selegiline hydrochloride clinical trials

Synonyms for selegiline hydrochloride
(-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride
(-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine monohydrochloride
(-)-Deprenil hydrochloride
(-)-Deprenyl hydrochloride
(-)-E-250 hydrochloride
(-)-N,alpha-Dimethyl-N-2-propynylbenzeneethanamine hydrochloride
(-)-Phenylisopropylmethylpropynylamine
(-)-selegiline hydrochloride
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
(R)-(-)-Deprenyl hydrochloride
(R)-(-)-N-?-Dimethyl-N-2-propynylbenzeneethanamine hydrochloride
(R)-(-)-N,alpha-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride
(R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride
14611-52-0
611S520
6W731X367Q
AC-18759
AKOS005166822
API0004151
AX8151001
Benzeneethanamine, N,alpha-dimethyl-N-2-propyn-1-yl-, hydrochloride (1:1), (alphaR)-
Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, hydrochloride, (R)-
BG0405
C13H17N.HCl
CAS-14611-52-0
CC-34395
CCG-100773
CCRIS 8571
CHEBI:9087
CHEMBL1200904
CPD000449328
CS-2764
D00785
DSSTox_CID_24584
DSSTox_GSID_44584
DSSTox_RID_80331
DTXSID9044584
E-250
Eldepryl
Eldepryl (TN)
Eldepryl hydrochloride
Ensam
FPF-1100
FPF1100
FT-0601539
HMS1569P05
HSDB 7183
HY-14199
IYETZZCWLLUHIJ-UTONKHPSSA-N
Jumex hydrochloride
K-4669
KS-00000059
KS-5098
L-Deprenalin HCl
L-deprenyl HCl
l-Deprenyl hydrochloride
LS-30157
MLS000758294
MLS001423947
MLS002153281
MLS002222269
NC00023
NC00605
NCGC00016708-01
NCGC00024994-06
NCGC00255797-01
Otrasel
Plurimen
Prestwick_846
Q27108267
R-(-)-Deprenyl (hydrochloride)
R-(-)-Deprenyl hydrochloride
R-(-)-Deprenyl hydrochloride, powder, >=98% (HPLC)
R-(-)deprenyl hydrochloride
R(-)-Deprenyl hydrochloride
SAM001246969
SAM002589926
SCHEMBL41392
Seledat
Selegiline Hcl
Selegiline hydrochloride (JAN/USP)
Selegiline hydrochloride [USAN:USP]
Selegiline hydrochloride [USAN]
Selegiline Hydrochloride 1.0 mg/ml in Methanol (as free base)
Selegiline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Selegiline hydrochloride, United States Pharmacopeia (USP) Reference Standard
SMR000449328
SR-01000597928
SR-01000597928-1
SR-01000597928-5
SR-01000597928-6
ST24035592
Tox21_110572
Tox21_110572_1
Tox21_301846
UNII-63G7R4955A component IYETZZCWLLUHIJ-UTONKHPSSA-N
UNII-6W731X367Q
Vivapryl
Xilopar
Zelapar
Zydis selegiline

US Patents and Regulatory Information for selegiline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acp Nimble SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074756-001 Nov 25, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Acp Nimble SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074744-001 Jan 27, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chartwell Molecules SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074565-001 Aug 2, 1996 DISCN No No   Start Trial   Start Trial   Start Trial
Rising SELEGILINE HYDROCHLORIDE selegiline hydrochloride CAPSULE;ORAL 206803-001 Apr 2, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Apotex SELEGILINE HYDROCHLORIDE selegiline hydrochloride CAPSULE;ORAL 075321-001 Dec 4, 1998 AB RX No Yes   Start Trial   Start Trial   Start Trial
Mylan SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074866-001 Nov 26, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for selegiline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006   Start Trial   Start Trial
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Dow
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.